Adapting to COVID-19: Adjudication and Oversight Group Management

A pharmaceutical company needed to run a COVID-19 therapeutic trial under extremely tight timelines while managing complex endpoint adjudication and oversight-committee operations. IQVIA's CEVA (Clinical Event Validation and Adjudication) team deployed specialized endpoint-adjudication services, compiling and managing study committees reviewing data on specific events, timepoints, or lab results needing external validation. The case study states "IQVIA CEVA was able to overcome tight timelines and meet client targets for their COVID-19 therapeutic trial" through "a unique blend of innovation, technical expertise, and adaptive strategies." No further metrics are given; full detail is gated behind a PDF.

The customer is anonymised in IQVIA’s own case study — not withheld by us.

IQVIA is the largest combined real-world-data and commercial-intelligence company in healthcare — its legacy IMS prescription and claims data underpins much of the industry's analytics.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.